RenovoRx, Inc. (RNXT)

RenovoRx's stock price has seen fluctuations over the past six months. Key events impacting the stock include the release of financial results, clinical trial updates, commercialization progress, and a patent allowance. The company reported its full-year 2025 financial results on March 30, 2026. The DMC for the Phase III TIGeR-PaC trial recommended continuing the study based on an interim data review. The company has reported growing clinical adoption and market demand for RenovoCath. RenovoRx secured its first notice of allowance for a Japanese patent covering its RenovoCath device.

The available information does not explicitly indicate demand seasonality for RenovoRx's products and services. The company has reported growing clinical demand and market demand for its RenovoCath device, suggesting a consistent and growing need for its targeted drug delivery solutions in oncology.

RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies and commercializing its RenovoCath device. The company's core business revolves around its TAMP therapy platform, designed for targeted therapeutic delivery to minimize toxicities. Major products include RenovoCath, an FDA-cleared device for delivering fluids to selected sites, and intra-arterial gemcitabine (IAG) via RenovoCath, a drug-device combination being evaluated in a Phase III trial for pancreatic and bile duct cancer.

RenovoRx, Inc. is headquartered in Mountain View, California. The company has been expanding its commercial footprint across the United States, with its RenovoCath device approved for purchase by an increasing number of cancer centers. RenovoRx also secured its first notice of allowance for a Japanese patent covering its RenovoCath device in April 2026.

RenovoRx has received positive recognition in the past year, enhancing its brand reputation. RenovoRx was named to Fast Company's annual list of the World's Most Innovative Companies of 2026. The growing clinical adoption of RenovoCath and increasing physician interest in targeted intra-arterial drug delivery also contribute positively to its reputation.

RenovoRx, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 10.97% to 19.78% of the company's stock is owned by institutional investors, 3.54% by insiders, and a significant portion (76.67%) by public companies and individual investors. Major institutional owners and shareholders include AIGH Capital Management LLC, Vanguard Group Inc, and Geode Capital Management, Llc, among others.